Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: Much more data, little new information

Journal of General Internal Medicine

Volumn 27, Issue 6, 2012, Pages 716-729

  Powers, Benjamin J ^a,b,c   Coeytaux, Remy R ^b,c   Dolor, Rowena J ^a,b,c   Hasselblad, Vic ^b,c   Patel, Uptal D ^a,b,c   Yancy Jr , William S ^a,b,c   Gray, Rebecca N ^b   Julian Irvine, R ^b   Kendrick, Amy S ^b   Sanders, Gillian D ^b,c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin converting enzyme inhibitors; angiotensin receptor blockers; direct renin inhibitors; hypertension; systematic review

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE; LIPID; LOSARTAN; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CLINICAL PROTOCOL; COUGHING; CREATININE BLOOD LEVEL; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EMBASE; ESSENTIAL HYPERTENSION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEADACHE; HEALTH PROGRAM; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY DISEASE; MEDLINE; PROTEINURIA; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; MIDDLE AGED; PROTEASE INHIBITORS; RENIN;

EID: 84862675799     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1938-8     Document Type: Review

References (126)

1. R Collins R Peto S MacMahon, et al. 1990 Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context Lancet 335 8693 827 838 1969567 1:STN:280:DyaK3c3gsFeruw%3D%3D 10.1016/0140-6736(90)90944-Z
2. S Lewington R Clarke N Qizilbash, et al. 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.[Erratum appears in Lancet. 2003 Mar 22;361(9362):1060] Lancet 360 9349 1903 1913 12493255 10.1016/S0140-6736(02)11911-8
3. JP Casas W Chua S Loukogeorgakis, et al. 2005 Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 9502 2026 2033 16338452 1:CAS:528:DC%2BD2MXht12ku7nJ 10.1016/S0140-6736(05)67814-2
4. Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveneness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Rockville, MD: Agency for Healthcare Research and Quality. November 2007. Available at: www.effectivehealthcare.ahrq.gov/ reports/final.cfm. Accessed October 31, 2010.
5. DB Matchar DC McCrory LA Orlando, et al. 2008 Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension Ann Intern Med 148 1 16 29 17984484
6. Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed October 31, 2011.
7. Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. York, UK: NHS Centre for Reviews and Dissemination. 2001 Mar. Report No.: CRD Report No. 4 (2nd edition).
8. RP Harris M Helfand SH Woolf, et al. 2001 Current methods of the US Preventive Services Task Force: a review of the process Am J Prev Med 20 3 Suppl 21 35 11306229 1:STN:280:DC%2BD38%2FgvVWquw%3D%3D 10.1016/S0749-3797(01)00261-6
9. DK Owens KN Lohr D Atkins, et al. 2010 AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-Care Program J Clin Epidemiol 63 5 513 523 19595577 10.1016/j.jclinepi.2009.03.009
10. D Atkins D Best PA Briss, et al. 2004 Grading quality of evidence and strength of recommendations BMJ 328 7454 1490 15205295 10.1136/bmj.328.7454.1490
11. K Andersen MH Weinberger B Egan, et al. 2008 Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial J Hypertens 26 3 589 599 18300872 1:CAS:528:DC%2BD1cXisVWhur0%3D 10.1097/HJH.0b013e3282f3ad9a
12. K Andersen MH Weinberger CM Constance, et al. 2009 Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension JRAAS - J Renin-Angiotensin-Aldosterone Syst 10 3 157 167 1:CAS:528:DC%2BD1MXhtlyru7jJ 10.1177/1470320309342407
13. DA Duprez MA Munger J Botha, et al. 2010 Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial J Hum Hypertens 24 9 600 608 20033075 1:CAS:528:DC%2BC3cXhtVCntb%2FM 10.1038/jhh.2009.107 Epub 2009 Dec 24
14. SD Solomon E Appelbaum WJ Manning, et al. 2009 Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 4 530 537 19153265 1:CAS:528:DC%2BD1MXpt1eksA%3D%3D 10.1161/CIRCULATIONAHA.108.826214
15. PB Akat TR Bapat MB Murthy, et al. 2010 Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension Indian J Pharmacol 42 3 153 156 20871766 1:CAS:528:DC%2BC3cXht1aqu7zE 10.4103/0253-7613.66838
16. J Amerena S Pappas JP Ouellet, et al. 2002 ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension J Int Med Res 30 6 543 552 12526280 1:CAS:528:DC%2BD3sXmvVSgug%3D%3D
17. L Argenziano B Trimarco 1999 Effect of eprosartan and enalapril in the treatment of elderly hypertensive Patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group Curr Med Res Opin 15 1 9 14 10216806 1:CAS:528:DyaK1MXitVehtro%3D 10.1185/ 03007999909115168
18. E Breeze EC Rake MD Donoghue, et al. 2001 Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension J Hum Hypertens 15 12 857 862 11773988 1:CAS:528:DC%2BD38Xks1OmtA%3D%3D 10.1038/sj.jhh.1001282
19. WJ Elliott 1999 Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group J Hum Hypertens 13 6 413 417 10408592 1:CAS:528:DyaK1MXjvFOjtrg%3D 10.1038/sj.jhh.1000816
20. I Gavras H Gavras 1999 Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group Curr Med Res Opin 15 1 15 24 10216807 1:CAS:528:DyaK1MXitVehtrs%3D 10.1185/03007999909115169
21. B Levine 1999 Effect of eprosartan and enalapril in the treatment of black hypertensive Patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group Curr Med Res Opin 15 1 25 32 10216808 1:CAS:528:DyaK1MXitVehtrg%3D 10.1185/03007999909115170
22. ACJ Avanza LM El Aouar JG Mill 2000 Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan Arq Bras Cardiol 74 2 103 117 10904284
23. AH Barnett SC Bain P Bouter, et al. 2004 Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.[erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731] N Engl J Med 351 19 1952 1961 15516696 1:CAS:528:DC%2BD2cXps1Wlt7g%3D 10.1056/NEJMoa042274
24. HR Black A Graff D Shute, et al. 1997 Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril J Hum Hypertens 11 8 483 489 9322828 1:CAS:528:DyaK2sXmtlCktrk%3D 10.1038/sj.jhh.1000482
25. T Celik A Iyisoy H Kursaklioglu, et al. 2005 The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive Patients: a randomized clinical study Clin Cardiol 28 6 298 302 16028466 10.1002/clc.4960280609
26. A Coca C Calvo J Garcia-Puig, et al. 2002 A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL) Clin Ther 24 1 126 138 11833827 1:CAS:528:DC%2BD38XhsVWls7k%3D 10.1016/S0149-2918(02)85010-X
27. C Cuspidi ML Muiesan L Valagussa, et al. 2002 Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study J Hypertens 20 11 2293 2300 12409969 1:CAS:528:DC%2BD38Xot12lsLY%3D 10.1097/00004872-200211000-00030
28. ML De Rosa P Cardace M Rossi, et al. 2002 Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients J Hum Hypertens 16 2 133 140 11850771 10.1038/sj.jhh.1001305 1:CAS:528:DC%2BD38Xhslartb8%3D
29. G Derosa AF Cicero L Ciccarelli, et al. 2003 A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus Clin Ther 25 7 2006 2021 12946547 1:CAS:528:DC%2BD3sXpvVyiu70%3D 10.1016/S0149-2918(03)80201-1
30. O Deyneli D Yavuz A Velioglu, et al. 2006 Effects of ACE inhibition and angiotension II receptor blockade on glomerular basement membrane protein excretion and change selectivity in type 2 diabetic patients JRAAS - J Renin-Angiotensin-Aldosterone Syst 7 2 98 103 1:CAS:528:DC%2BD28XhtVGis7bF 10.3317/jraas.2006.016
31. K Eguchi K Kario K Shimada 2003 Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension Am J Cardiol 92 5 621 624 12943892 1:CAS:528:DC%2BD3sXms12isb8%3D 10.1016/S0002-9149(03)00739-2
32. L Fernandez-Campo MT Grande J Diego, et al. 2009 Effect of different antihypertensive treatments on Ras, MAPK and Akt activation in hypertension and diabetes Clin Sci 116 2 165 173 18588512 1:CAS:528:DC%2BD1cXhsV2ltLfK 10.1042/CS20080119
33. R Fogari A Mugellini A Zoppi, et al. 2002 Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients Am J Hypertens 15 4 Pt 1 316 320 11991216 1:CAS:528:DC%2BD38XktlyktLY%3D 10.1016/S0895-7061(01)02340-8
34. R Fogari A Mugellini A Zoppi, et al. 2004 Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension Eur J Clin Pharmacol 59 12 863 868 14747881 1:CAS:528:DC%2BD2cXhsVOgt7g%3D 10.1007/s00228-003-0717-9
35. R Fogari A Zoppi P Preti, et al. 2001 Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women Am J Hypertens 14 9 Pt 1 921 926 11587159 1:CAS:528:DC%2BD3MXns1ynt7w%3D 10.1016/S0895-7061(01)02140-9
36. R Fogari A Mugellini A Zoppi, et al. 2006 Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients J Hum Hypertens 20 3 177 185 16306998 1:CAS:528:DC%2BD28XhsVehs7g%3D 10.1038/sj.jhh.1001964
37. R Fogari G Derosa I Ferrari, et al. 2008 Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation Am J Hypertens 21 9 1034 1039 18566593 1:CAS:528:DC%2BD1cXhtValsLrF 10.1038/ajh.2008.217
38. V Formosa A Bellomo A Iori, et al. 2009 The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly Arch Gerontol Geriatr 49 Suppl 1 95 101 19836621 1:CAS:528: DC%2BD1MXht1OgtLjJ 10.1016/j.archger.2009.09.017
39. H Franke 1997 Antihypertensive effects of candesartan cilexetil, enalapril and placebo J Hum Hypertens 11 Suppl 2 S61 S62 9331010 1:CAS:528:DyaK2sXms1Sisbk%3D
40. L Ghiadoni A Magagna D Versari, et al. 2003 Different effect of antihypertensive drugs on conduit artery endothelial function Hypertension 41 6 1281 1286 12719441 1:CAS:528:DC%2BD3sXktVyntb4%3D 10.1161/01.HYP.0000070956. 57418.22
41. U Guntekin Y Gunes M Tuncer, et al. 2008 Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients Adv Ther 25 8 775 786 18670740 1:CAS:528:DC%2BD1cXhsV2ksbjN 10.1007/s12325-008-0083-1
42. J Hasford A Mimran WR Simons 2002 A population-based European cohort study of persistence in newly diagnosed hypertensive patients J Hum Hypertens 16 8 569 575 12149663 1:STN:280:DC%2BD38vgtVahtQ%3D%3D 10.1038/sj.jhh.1001451
43. RC Hermida DE Ayala Y Khder, et al. 2008 Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial Clin Ther 30 1 108 120 18343247 1:CAS:528:DC%2BD1cXhtVWlt7fO 10.1016/j.clinthera.2008.01.012
44. K Hosohata S Saito K Asayama, et al. 2007 Progress report on The Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study: status at February 2004 Clin Exp Hypertens (New York) 29 1 69 81 10.1080/10641960601096976
45. BE Karlberg LE Lins K Hermansson 1999 Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group J Hypertens 17 2 293 302 10067800 1:CAS:528:DyaK1MXktlKhsr4%3D 10.1097/00004872-199917020-00015
46. H Kavgaci A Sahin H Onder Ersoz, et al. 2002 The effects of losartan and fosinopril in hypertensive type 2 diabetic patients Diabetes Res Clin Pract 58 1 19 25 12161053 1:CAS:528:DC%2BD38XlvVWjtbc%3D 10.1016/S0168-8227(02)00102-X
47. RA Kloner J Neutel EM Roth, et al. 2008 Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial Ann Pharmacother 42 11 1552 1562 18827176 1:CAS:528:DC%2BD1cXhsVOgurfJ 10.1345/aph.1L076
48. N Koylan E Acarturk A Canberk, et al. 2005 Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension Patients: a multicenter, open-labeled, three-armed study Blood Press Suppl 1 23 31 16060413 10.1080/08038020510040649 1:CAS:528:DC%2BD2MXpsFGlsb4%3D
49. Y Lacourciere A Belanger C Godin, et al. 2000 Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy Kidney Int 58 2 762 769 10916100 1:CAS:528: DC%2BD3cXlvFags7k%3D 10.1046/j.1523-1755.2000.00224.x
50. Y Lacourciere JM Neutel G Davidai, et al. 2006 A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring Am J Hypertens 19 1 104 112 16461201 1:CAS:528:DC%2BD28Xht1Ort7s%3D 10.1016/j.amjhyper.2005.10.001
51. P Larochelle JM Flack TC Marbury, et al. 1997 Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators Am J Cardiol 80 12 1613 1615 9416950 1:CAS:528:DyaK1cXjtlKnug%3D%3D 10.1016/S0002-9149(97)00784-4
52. E Malacco M Santonastaso NA Vari, et al. 2004 Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.[erratum appears in Clin Ther. 2004 Jul;26(7):1185] Clin Ther 26 6 855 865 15262456 1:CAS:528:DC%2BD2cXmsVSis74%3D 10.1016/S0149-2918(04)90129-4
53. E Malacco S Omboni M Volpe, et al. 2010 Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: The ESPORT study J Hypertens 28 11 2342 2350 20829713 1:CAS:528:DC%2BC3cXht1yktb%2FI 10.1097/HJH.0b013e32833e116b
54. JM Mallion DC Bradstreet L Makris, et al. 1995 Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension J Hypertens, Suppl 13 1 S35 S41 1:CAS:528:DyaK2MXpsVWlsL8%3D 10.1097/00004872-199507001-00005
55. K Malmqvist T Kahan M Dahl 2000 Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide Am J Hypertens 13 5 Pt 1 504 511 10826401 1:CAS:528:DC%2BD3cXjvFSrurY%3D 10.1016/S0895-7061(99)00264-2
56. H Matsuda K Hayashi T Saruta 2003 Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease J Hum Hypertens 17 4 271 276 12692572 1:CAS:528: DC%2BD3sXivVWku7g%3D 10.1038/sj.jhh.1001543
57. GT McInnes KP O'Kane H Istad, et al. 2000 Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients J Hum Hypertens 14 4 263 269 10805052 1:CAS:528:DC%2BD3cXjtVyqs74%3D 10.1038/sj.jhh.1000997
58. J Menne C Farsang L Deak, et al. 2008 Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial J Hypertens 26 9 1860 1867 18698222 1:CAS:528:DC%2BD1cXpvFynsbs%3D 10.1097/HJH.0b013e32830508aa
59. A Mimran L Ruilope L Kerwin, et al. 1998 A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension J Hum Hypertens 12 3 203 208 9579771 1:CAS:528:DyaK1cXitlChtrk%3D 10.1038/sj.jhh.1000591
60. CE Mogensen S Neldam I Tikkanen, et al. 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 7274 1440 1444 11110735 1:CAS:528:DC%2BD3MXjsFCkuw%3D%3D 10.1136/bmj.321.7274.1440
61. DP Naidoo P Sareli F Marin, et al. 1999 Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies Adv Ther 16 5 187 199 10915394 1:CAS:528:DC%2BD3cXls1Ojtw%3D%3D
62. T Nakamura K Kawachi Y Saito, et al. 2009 Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension Int Hear J 50 4 501 512 1:CAS:528:DC%2BD1MXptlOnur0%3D 10.1536/ihj.50.501
63. JM Neutel WH Frishman S Oparil, et al. 1999 Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension Am J Ther 6 3 161 166 10423659 1:STN:280:DyaK1MzlsVWrtg%3D%3D 10.1097/00045391-199905000-00007
64. S Nielsen J Dollerup B Nielsen, et al. 1997 Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study Nephrol Dial Transplant 12 Suppl 2 19 23 9269694
65. I Tikkanen P Omvik HA Jensen 1995 Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension J Hypertens 13 11 1343 1351 8984133 1:CAS:528:DyaK28XkvFGgtA%3D%3D 10.1097/00004872-199511000-00017
66. IK Onal B Altun ED Onal, et al. 2009 Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment Eur J Intern Med 20 4 369 372 19524176 1:CAS:528:DC%2BD1MXnt1Ggu7Y%3D 10.1016/j.ejim.2008.10.003
67. F Rabbia B Silke R Carra, et al. 2004 Heart rate variability and baroreflex sensitivity during fosinopril, irbesartan and atenolol therapy in hypertension Clin Drug Investig 24 11 651 659 17523728 1:CAS:528: DC%2BD2MXhsV2jtQ%3D%3D 10.2165/00044011-200424110-00004
68. S Ragot A Ezzaher A Meunier, et al. 2002 Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study J Hum Hypertens 16 12 865 873 12522468 1:CAS:528:DC%2BD3sXhs1Ohug%3D%3D 10.1038/sj.jhh.1001494
69. M Rajzer M Klocek K Kawecka-Jaszcz 2003 Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension Am J Hypertens 16 6 439 444 12799091 1:CAS:528:DC%2BD3sXksVKjsbw%3D 10.1016/S0895-7061(03)00052-9
70. A Rehman SB Ismail L Naing, et al. 2007 Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malayhypertensive subjects with a known genetic profile Am J Hypertens 20 2 184 189 17261465 1:CAS:528:DC%2BD2sXpvV2isg%3D%3D 10.1016/j.amjhyper.2006.07.015
71. NR Robles E Angulo J Grois, et al. 2004 Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives Ren Fail 26 4 399 404 15462108 1:CAS:528:DC%2BD2cXntlyit7c%3D 10.1081/JDI-120039824
72. A Roca-Cusachs W Oigman L Lepe, et al. 1997 A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension Acta Cardiol 52 6 495 506 9542575 1:STN:280:DyaK1c3gtlOjsA%3D%3D
73. EA Rosei D Rizzoni ML Muiesan, et al. 2005 Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus J Hypertens 23 2 435 444 15662233 1:CAS:528:DC%2BD2MXmtFCgtQ%3D%3D 10.1097/00004872- 200502000-00027
74. D Ruff LP Gazdick R Berman, et al. 1996 Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension J Hypertens 14 2 263 270 8728306 1:CAS:528: DyaK28XivFKhtbw%3D 10.1097/00004872-199602000-00017
75. L Ruilope B Jager B Prichard 2001 Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial Blood Press 10 4 223 229 11800061 1:CAS:528:DC%2BD38XjvVWrsg%3D%3D 10.1080/08037050152669747
76. S Saito K Asayama T Ohkubo, et al. 2004 The second progress report on the Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study Blood Press Monit 9 5 243 247 15472496 10.1097/00126097-200410000-00003
77. RA Sanchez LD Masnatta C Pesiney, et al. 2008 Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives J Hypertens 26 12 2393 2398 19008718 1:CAS:528:DC%2BD1cXhtlKrtrjL 10.1097/HJH.0b013e328312677e
78. R Scaglione C Argano T Di Chiara, et al. 2007 Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients J Hum Hypertens 21 4 307 315 17301824 1:CAS:528:DC%2BD2sXivVSmu7k%3D
79. B Schieffer C Bunte J Witte, et al. 2004 Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease J Am Coll Cardiol 44 2 362 368 15261932 1:CAS:528:DC%2BD2cXlslyhsbw%3D 10.1016/j.jacc.2004.03.065
80. MT Schram FJ van Ittersum A Spoelstra-de Man, et al. 2005 Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial J Hum Hypertens 19 6 429 437 15647778 1:CAS:528:DC%2BD2MXkt1CktL0%3D 10.1038/sj.jhh.1001812
81. AM Sengul Y Altuntas A Kurklu, et al. 2006 Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension Diabetes Res Clin Pract 71 2 210 219 16112244 1:CAS:528:DC%2BD28XlvVGnsw%3D%3D 10.1016/j.diabres.2005.06.010
82. BI Shand 2000 Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension J Hum Hypertens 14 5 305 309 10822316 1:CAS:528:DC%2BD3cXjvFSqsLc%3D 10.1038/sj.jhh.1001011
83. BI Shand KL Lynn 2000 A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease Clin Nephrol 54 5 427 428 11105808 1:STN:280: DC%2BD3Mzgs12lug%3D%3D
84. Y Shibasaki H Masaki T Nishiue, et al. 2002 Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease Nephron 90 3 256 261 11867945 1:CAS:528: DC%2BD38XhsFSis7k%3D 10.1159/000049060
85. M Sonoda T Aoyagi K Takenaka, et al. 2008 A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors Int Hear J 49 1 95 103 1:CAS:528:DC%2BD1cXltFOktbs%3D 10.1536/ihj.49.95
86. LA Souza-Barbosa SE Ferreira-Melo S Ubaid-Girioli, et al. 2006 Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade J Clin Hypertens 8 11 803 809 1:CAS:528:DC%2BD28XhtlWnu73P 10.1111/j.1524-6175.2006.05663.x quiz 10-1
87. J Spinar J Vitovec M Soucek, et al. 2009 CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers Vnitrni Lekarstvi 55 5 481 488 19514614 1:CAS:528:DC%2BD1MXntlOmu7k%3D
88. AM Spoelstra-de Man FJ van Ittersum MT Schram, et al. 2006 Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension J Hum Hypertens 20 8 599 611 16673014 1:CAS:528:DC%2BD28XntVWltb8%3D 10.1038/sj.jhh.1002025
89. MA Tedesco F Natale R Calabro 2006 Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients J Clin Hypertens 8 9 634 641 1:CAS:528:DC%2BD28XhtVeqtr3N 10.1111/j.1524-6175. 2006.05504.x
90. R Townsend B Haggert C Liss, et al. 1995 Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension Clin Ther 17 5 911 923 8595643 1:STN:280:DyaK287mslSiuw%3D%3D 10.1016/0149-2918(95)80069-7
91. Y Uchiyama-Tanaka Y Mori N Kishimoto, et al. 2005 Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension Kidney & Blood Press Res 28 2 111 116 1:CAS:528:DC%2BD2MXjtlWgs7o%3D 10.1159/000084254
92. P Verdecchia G Schillaci GP Reboldi, et al. 2000 Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study Blood Press Monit 5 3 187 193 10915233 1:STN:280:DC%2BD3cvntFSrtw%3D%3D 10.1097/00126097- 200006000-00008
93. M Veronesi AF Cicero MG Prandin, et al. 2007 A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice Vasc Health & Risk Manag 3 6 999 1005
94. B Williams P Gosse L Lowe, et al. 2006 The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I) J Hypertens 24 1 193 200 16331118 1:CAS:528:DC%2BD2MXht1yitLvI 10.1097/01.hjh.0000194364.11516.ab
95. D Xu J Liu C Ji, et al. 2007 Effects of telmisartan on hypertensive patients with dyslipidemia and insulin resistance J of Geriatr Cardiol 4 3 149 152 1:CAS:528:DC%2BD1cXjslWgsA%3D%3D
96. MI Yilmaz A Sonmez K Caglar, et al. 2007 Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome Nephrology 12 2 147 153 17371337 1:CAS:528:DC%2BD2sXltFWnsLo%3D 10.1111/j.1440-1797.2007.00764.x
97. S Zhu Y Liu L Wang, et al. 2008 Transforming growth factor-(beta)(1) is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker Nephrol Dial Transplant 23 9 2841 2846 18390891 1:CAS:528:DC%2BD1cXhtF2qtLjE 10.1093/ndt/gfn159
98. G Mazzaglia LG Mantovani MC Sturkenboom, et al. 2005 Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care J Hypertens 23 11 2093 2100 16208153 1:CAS:528:DC%2BD2MXhtVOitLbE 10.1097/01.hjh.0000186832. 41125.8a
99. J Cotter P Oliveira P Cunha, et al. 2008 Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system Rev Port Cardiol 27 11 1395 1404 19227807
100. TE Delea C Taneja A Moynahan, et al. 2007 Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension Am J Health Syst Pharm 64 11 1187 1196 17519461 1:CAS:528:DC%2BD2sXmvVWmsLc%3D 10.2146/ajhp060380
101. B Malde J Regalado PA Greenberger 2007 Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Ann Allergy Asthma Immunol 98 1 57 63 17225721 1:CAS:528:DC%2BD2sXhsF2htLo%3D 10.1016/S1081-1206(10)60860-5
102. S Ozturk F Sar O Bengi-Bozkurt, et al. 2009 Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis Kidney Blood Press Res 32 4 268 275 19776644 10.1159/000239765
103. A Sato M Tabata K Hayashi, et al. 2003 Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy Clin Exp Nephrol 7 3 215 220 14586718 1:CAS:528:DC%2BD3sXotF2ktr4%3D 10.1007/s10157-003-0227-1
104. JP Gregoire J Moisan R Guibert, et al. 2001 Tolerability of antihypertensive drugs in a community-based setting Clin Ther 23 5 715 726 11394730 1:CAS:528:DC%2BD3MXks1Srt78%3D 10.1016/S0149-2918(01)80021-7
105. FJ Mackay GL Pearce RD Mann 1999 Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 47 1 111 114 10073748 1:CAS:528:DyaK1MXht12ju7c%3D 10.1046/j.1365-2125.1999.00855.x
106. BS Bloom 1998 Continuation of initial antihypertensive medication after 1 year of therapy Clin Ther 20 4 671 681 9737827 1:STN:280:DyaK1cvgslyntw%3D%3D 10.1016/S0149-2918(98)80130-6
107. C Bourgault M Senecal M Brisson, et al. 2005 Persistence and discontinuation patterns of antihypertensive therapy among newly treated Patients: a population-based study J Hum Hypertens 19 8 607 613 15920457 1:CAS:528:DC%2BD2MXmt1ymsrc%3D 10.1038/sj.jhh.1001873
108. TA Burke MC Sturkenboom SE Lu, et al. 2006 Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice J Hypertens 24 6 1193 1200 16685222 10.1097/01.hjh.0000226211.95936.f5
109. PR Conlin WC Gerth J Fox, et al. 2001 Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes Clin Ther 23 12 1999 2010 11813934 1:CAS:528:DC%2BD38XhtVyltLY%3D 10.1016/S0149-2918(01)80152-1
110. E Degli Esposti A Sturani M Di Martino, et al. 2002 Long-term persistence with antihypertensive drugs in new patients J Hum Hypertens 16 6 439 444 12037702 1:STN:280:DC%2BD383ps1ygtw%3D%3D 10.1038/sj.jhh.1001418
111. L Degli Esposti E Degli Esposti G Valpiani, et al. 2002 A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy Clin Ther 24 8 1347 1357 12240784 10.1016/S0149-2918(02)80039-X discussion 6
112. JA Erkens MM Panneman OH Klungel, et al. 2005 Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study Pharmacoepidemiol Drug Saf 14 11 795 803 16178043 10.1002/pds.1156
113. MA Marentette WC Gerth DK Billings, et al. 2002 Antihypertensive persistence and drug class Can J Cardiol 18 6 649 656 12107422 1:CAS:528:DC%2BD38XlvFWntLY%3D
114. J Wogen CA Kreilick RC Livornese, et al. 2003 Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting J Managed Care Pharm 9 5 424 429
115. J Hasford D Schroder-Bernhardi M Rottenkolber, et al. 2007 Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study Eur J Clin Pharmacol 63 11 1055 1061 17701032 10.1007/s00228-007-0340-2
116. J Lachaine RJ Petrella E Merikle, et al. 2008 Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data Can J Cardiol 24 4 269 273 18401466 10.1016/S0828-282X(08)70175-2
117. BV Patel RA Remigio-Baker D Mehta, et al. 2007 Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States J Clin Hypertens 9 9 692 700 10.1111/j.1524-6175.2007.07194.x
118. LA Simons M Ortiz G Calcino 2008 Persistence with antihypertensive medication: Australia-wide experience, 2004-2006 Med J Aust 188 4 224 227 18279129
119. D Meltzer A Basu R Conti 2010 The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research PharmacoEconomics 28 10 843 853 20831292 10.2165/11539400-000000000-00000
120. WL Baker CI Coleman J Kluger, et al. 2009 Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease Ann Intern Med 151 12 861 871 20008762
121. RM Califf JJ McMurray RR Holman, et al. 2010 Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 16 1477 1490 20228403 10.1056/NEJMoa1001121
122. Dream Trial Investigators J Bosch S Yusuf, et al. 2006 Effect of ramipril on the incidence of diabetes N Engl J Med 355 15 1551 1562 16980380 10.1056/NEJMoa065061
123. P Jong C Demers RS McKelvie, et al. 2002 Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials J Am Coll Cardiol 39 3 463 470 11823085 1:CAS:528:DC%2BD38XitFOju7g%3D 10.1016/S0735-1097(01) 01775-2
124. S Balamuthusamy L Srinivasan M Verma, et al. 2008 Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Am Heart J 155 5 791 805 18440325 1:CAS:528:DC%2BD1cXlsFCht78%3D 10.1016/j.ahj.2008.01.031
125. I Sipahi SM Debanne DY Rowland, et al. 2010 Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 7 627 636 20542468 1:CAS:528:DC%2BC3cXotVWqu7w%3D 10.1016/S1470-2045(10) 70106-6
126. Emerging Risk Factors Collaboration D Wormser S Kaptoge, et al. 2011 Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies Lancet 377 9771 1085 1095 21397319